Cerus Corp (CERS) company profile

Cerus Corporation is a biomedical company focused on the field of blood transfusion safety. The company develops and commercializes the INTERCEPT Blood System, which is designed to reduce the risk of transfusion-transmitted infections by targeting and inactivating pathogens such as viruses, bacteria, and parasites in donated blood components. Its commercial product line includes systems for platelets, plasma, and cryoprecipitation, while a pathogen reduction system for red blood cells remains in development. The company’s primary customers and end users include blood centers, hospitals, clinicians, and governmental entities such as the Biomedical Advanced Research and Development Authority and the United States Department of Defense.

Cerus operates primarily in the United States and international markets, including Europe, the Middle East, and other regions, with direct operations and customer relationships spanning countries such as France, the Netherlands, and China. The company maintains its principal executive offices in Concord, California.

Summary of the business section of Cerus's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“As of December 31, 2025, we had 275 employees company-wide.”